Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous close | 13.07 |
| Open | 13.08 |
| Bid | 13.00 x 4000 |
| Ask | 13.20 x 3000 |
| Day's range | 13.01 - 13.08 |
| 52-week range | 13.01 - 17.11 |
| Volume | |
| Avg. volume | 1,825,653 |
| Market cap | 41.228B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 36.19 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.64 (4.90%) |
| Ex-dividend date | 28 Sept 2023 |
| 1y target est | N/A |
- GlobeNewswire
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its partner Takeda (TSE:4502/NYSE:TAK) received notification that the Com
- Business Wire
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
OSAKA, Japan & CAMBRIDGE, Mass., April 26, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when de
- PR Newswire
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of NBI-1065845 in adult subjects with major depressive disorder (MDD). NBI-1065845 is an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) in development as a potential treatment for patients with MDD who have not be
